Net Profit Margin
since 2005
Calculation
Merck & Co. Inc., net profit margin, long-term trends, calculation
| Net profit margin | = | 100 | × | Net income attributable to Merck & Co., Inc.1 | ÷ | Sales1 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 26.68% | = | 100 | × | 17,117) | ÷ | 64,168) |
| Dec 31, 2023 | 0.61% | = | 100 | × | 365) | ÷ | 60,115) |
| Dec 31, 2022 | 24.49% | = | 100 | × | 14,519) | ÷ | 59,283) |
| Dec 31, 2021 | 26.79% | = | 100 | × | 13,049) | ÷ | 48,704) |
| Dec 31, 2020 | 14.72% | = | 100 | × | 7,067) | ÷ | 47,994) |
| Dec 31, 2019 | 21.01% | = | 100 | × | 9,843) | ÷ | 46,840) |
| Dec 31, 2018 | 14.71% | = | 100 | × | 6,220) | ÷ | 42,294) |
| Dec 31, 2017 | 5.97% | = | 100 | × | 2,394) | ÷ | 40,122) |
| Dec 31, 2016 | 9.85% | = | 100 | × | 3,920) | ÷ | 39,807) |
| Dec 31, 2015 | 11.25% | = | 100 | × | 4,442) | ÷ | 39,498) |
| Dec 31, 2014 | 28.22% | = | 100 | × | 11,920) | ÷ | 42,237) |
| Dec 31, 2013 | 10.00% | = | 100 | × | 4,404) | ÷ | 44,033) |
| Dec 31, 2012 | 13.05% | = | 100 | × | 6,168) | ÷ | 47,267) |
| Dec 31, 2011 | 13.05% | = | 100 | × | 6,272) | ÷ | 48,047) |
| Dec 31, 2010 | 1.87% | = | 100 | × | 861) | ÷ | 45,987) |
| Dec 31, 2009 | 47.04% | = | 100 | × | 12,901) | ÷ | 27,428) |
| Dec 31, 2008 | 32.74% | = | 100 | × | 7,808) | ÷ | 23,850) |
| Dec 31, 2007 | 13.54% | = | 100 | × | 3,275) | ÷ | 24,198) |
| Dec 31, 2006 | 19.59% | = | 100 | × | 4,434) | ÷ | 22,636) |
| Dec 31, 2005 | 21.04% | = | 100 | × | 4,631) | ÷ | 22,012) |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in millions
- Net income attributable to Merck & Co., Inc.
- The net income exhibits significant volatility throughout the observed period. Initially, it declined from 4,631 million USD in 2005 to a low point of 861 million USD in 2010. Subsequently, a fluctuating recovery occurred, reaching a peak of 14,519 million USD in 2021. Notably, there is an abrupt drop to 365 million USD in 2023, followed by a sharp increase to 17,117 million USD in 2024. This pattern indicates considerable fluctuations potentially influenced by extraordinary items, restructuring, or external factors.
- Sales
- Sales revenue generally showed an upward trend from 22,012 million USD in 2005 to 64,168 million USD in 2024, more than doubling over the period. There was a significant jump between 2009 and 2010 from 27,428 million USD to 45,987 million USD, which could indicate an acquisition or substantial growth event. Some marginal declines and plateaus are noted, particularly in the years following 2010, but the overall trajectory remains positive with steady growth towards the later years.
- Net profit margin
- The net profit margin display substantial variability. The margin peaked at 47.04% in 2009 but plummeted sharply the following year to 1.87% in 2010. After this, it stabilizes somewhat, fluctuating between approximately 6% and 28% across most years. There is an anomalous drop to 0.61% in 2023 corresponding with the dip in net income. The margin rebounds strongly in 2024 to 26.68%, aligning with the sales and net income growth in that year. This variability suggests volatile profitability influenced by non-recurring gains or losses, cost fluctuations, or shifts in operational efficiency.
- Overall insights
- The data reveals a company experiencing periods of intense financial fluctuation, particularly around the years 2009-2010 and 2023-2024. The substantial increase in sales post-2009 indicates a possible transformative event such as a merger or acquisition. Profitability does not consistently track sales growth, which suggests challenges in cost management or the impact of extraordinary items affecting net income. The dramatic swings in net income and profit margin point to episodic factors impacting financial performance rather than steady operational trends.
Comparison to Competitors
Merck & Co. Inc., net profit margin, long-term trends, comparison to competitors
| Merck & Co. Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 26.68% | 7.59% | 12.77% | -18.53% | 16.33% | 23.51% | 1.68% | 15.84% | 12.62% | 31.07% | 14.77% | -4.86% |
| Dec 31, 2023 | 0.61% | 8.95% | 24.96% | 17.83% | 19.94% | 15.36% | 21.03% | 41.28% | 3.56% | 30.14% | 13.99% | 36.68% |
| Dec 31, 2022 | 24.49% | 20.39% | 26.42% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 31.01% | 35.64% | 15.47% | 37.20% |
| Dec 31, 2021 | 26.79% | 20.54% | 24.25% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.76% | 50.25% | 19.70% | 30.92% |
| Dec 31, 2020 | 14.72% | 10.08% | 29.97% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 22.53% | 41.35% | 19.79% | 43.70% |
| Dec 31, 2019 | 21.01% | 23.69% | 35.32% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 31.45% | 26.91% | 14.47% | 28.27% |
| Dec 31, 2018 | 14.71% | 17.36% | 37.25% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 20.79% | 36.42% | 12.06% | 68.80% |
| Dec 31, 2017 | 5.97% | 18.82% | 9.08% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 40.55% | 20.41% | 10.64% | 10.59% |
| Dec 31, 2016 | 9.85% | 23.22% | 35.27% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 13.66% | 18.42% | 11.06% | -6.58% |
| Dec 31, 2015 | 11.25% | 22.50% | 33.13% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 14.25% | 15.50% | 11.64% | -53.89% |
| Dec 31, 2014 | 28.22% | 8.89% | 26.69% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 18.42% | 12.34% | 11.22% | -127.25% |
| Dec 31, 2013 | 10.00% | 21.97% | 27.93% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 42.65% | 20.16% | 9.73% | -36.72% |
| Dec 31, 2012 | 13.05% | 28.70% | 26.11% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 24.70% | 54.43% | 9.42% | -7.01% |
| Dec 31, 2011 | 13.05% | — | 24.08% | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 14.84% | -49.74% | 11.34% | 2.10% |
| Dec 31, 2010 | 1.87% | — | 31.56% | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 12.18% | -22.76% | 9.60% | -526.35% |
| Dec 31, 2009 | 47.04% | — | 32.09% | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 17.27% | -17.88% | 8.41% | -630.27% |
| Dec 31, 2008 | 32.74% | — | 28.57% | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 16.78% | -34.69% | 9.47% | -262.02% |
| Dec 31, 2007 | 13.54% | — | 22.12% | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 16.82% | -84.46% | 7.81% | -196.61% |
| Dec 31, 2006 | 19.59% | — | 21.29% | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 39.98% | -161.30% | 4.46% | -95.63% |
| Dec 31, 2005 | 21.04% | — | 30.56% | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 15.76% | -144.19% | 8.48% | -126.43% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Merck & Co. Inc., net profit margin, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Merck & Co. Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Dec 31, 2024 | 26.68% | 12.30% |
| Dec 31, 2023 | 0.61% | 17.95% |
| Dec 31, 2022 | 24.49% | 22.55% |
| Dec 31, 2021 | 26.79% | 23.38% |
| Dec 31, 2020 | 14.72% | 14.07% |
| Dec 31, 2019 | 21.01% | 23.22% |
| Dec 31, 2018 | 14.71% | 19.82% |
| Dec 31, 2017 | 5.97% | 13.06% |
| Dec 31, 2016 | 9.85% | 20.78% |
| Dec 31, 2015 | 11.25% | 21.17% |
| Dec 31, 2014 | 28.22% | 21.24% |
| Dec 31, 2013 | 10.00% | 21.99% |
| Dec 31, 2012 | 13.05% | 18.53% |
| Dec 31, 2011 | 13.05% | 15.70% |
| Dec 31, 2010 | 1.87% | 15.16% |
| Dec 31, 2009 | 47.04% | 25.73% |
| Dec 31, 2008 | 32.74% | 18.17% |
| Dec 31, 2007 | 13.54% | 15.90% |
| Dec 31, 2006 | 19.59% | 22.24% |
| Dec 31, 2005 | 21.04% | 18.33% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Merck & Co. Inc., net profit margin, long-term trends, comparison to industry (health care)
| Merck & Co. Inc. | Health Care | |
|---|---|---|
| Dec 31, 2024 | 26.68% | 7.02% |
| Dec 31, 2023 | 0.61% | 9.24% |
| Dec 31, 2022 | 24.49% | 11.62% |
| Dec 31, 2021 | 26.79% | 12.42% |
| Dec 31, 2020 | 14.72% | 8.45% |
| Dec 31, 2019 | 21.01% | 11.58% |
| Dec 31, 2018 | 14.71% | 9.92% |
| Dec 31, 2017 | 5.97% | 8.05% |
| Dec 31, 2016 | 9.85% | 10.68% |
| Dec 31, 2015 | 11.25% | 11.77% |
| Dec 31, 2014 | 28.22% | 12.15% |
| Dec 31, 2013 | 10.00% | 12.81% |
| Dec 31, 2012 | 13.05% | 11.86% |
| Dec 31, 2011 | 13.05% | 10.50% |
| Dec 31, 2010 | 1.87% | 10.48% |
| Dec 31, 2009 | 47.04% | 15.08% |
| Dec 31, 2008 | 32.74% | 11.35% |
| Dec 31, 2007 | 13.54% | 11.02% |
| Dec 31, 2006 | 19.59% | 13.95% |
| Dec 31, 2005 | 21.04% | 13.38% |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).